SGLT2 Inhibitors Linked to Less Renal Deterioration Across All CKD Stages
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.
Type 2 Diabetes
HbA1c Variability Linked to Cardiovascular Disease Risk
For patients with newly diagnosed type 2 diabetes, visit-to-visit HbA1c variability is associated with increased risks for cardiovascular disease and microvascular complications.
Variability in Sleep Duration May Affect Blood Glucose Control in Diabetes
Sleep may be an important modifiable factor in disease management in patients with type 2 diabetes, especially variation in sleep duration.
Comparison of Canagliflozin and GLP-1 Receptor Agonists in Type 2 Diabetes
Treatment with canagliflozin was associated with similar reductions in HbA1c compared with any dose of a GLP-1 receptor agonist, with better treatment adherence and lower annual costs.
Reduced Risk for HF Hospitalization With Empagliflozin vs Other Antidiabetic Agents
Treatment with empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was associated with reduced risk of hospitalization for heart failure when compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists.
Men With T2D, Osteoarthritis Experience More Severe Joint Pain With Insulin Use
A hospital-based cohort study found sex heterogeneity in the severity of osteoarthritis symptoms in type 2 diabetes, and an association between insulin treatment and pain severity in men.
Acute Pancreatitis in Childhood May Increase Risk for Type 2 Diabetes
Patients with a history of acute pancreatitis may require closer follow-up and control of diabetes risk factors in young adulthood.
Surgical Treatment for T2D in Adolescents Linked to Lower Risk for Kidney Disease
For severely obese adolescents with type 2 diabetes, medical therapy is associated with increased odds of diabetic kidney disease at five years compared with metabolic bariatric surgery.
Vitamin D, Omega-3 Do Not Benefit Kidney Health in T2D
Supplementation with vitamin D3 or omega-3 fatty acids does not result in a significant difference in change in estimated glomerular filtration rate at five years versus placebo among adults with type 2 diabetes.
Lower Risk for Gout With SGLT2 Inhibitors vs GLP-1 Receptor Agonists in T2D
Researchers assessed the risk for gout among adults receiving a sodium-glucose cotransporter 2 inhibitor vs a glucagon-like peptide-1 receptor agonist.
Next post in Type 2 Diabetes
